肿瘤细胞治疗研究
英文原题：Chimeric antigen receptor T-cell therapy.
Chimeric antigen receptor T-cell therapy.
CAR-T 细胞疗法是复发或难治性弥漫大B细胞淋巴瘤或急性淋巴细胞白血病患者有前景的新选择。
CAR-T 细胞疗法是复发或难治性弥漫大B细胞淋巴瘤或急性淋巴细胞白血病患者有希望的新选择。它们提高了完全缓解率和实现长期缓解的机会。CAR-T 细胞是经过特殊修饰的淋巴细胞，旨在刺激人体自身免疫系统靶向恶性细胞。该过程包括初始采集患者自身的T细胞、基因修饰、T细胞扩增，然后回输。细胞因子释放综合征是CAR-T 细胞疗法的主要短期并发症。其表现通常类似感染性休克，并可致命。免疫效应细胞相关神经毒性综合征是另一种主要短期并发症。它表现为一系列神经功能缺损，从头痛、谵妄和焦虑到癫痫发作和昏迷。CAR-T 细胞疗法在其他癌症中已有早期有希望的结果。这些包括套细胞淋巴瘤、多发性骨髓瘤以及一些实体器官肿瘤，如多形性胶质母细胞瘤。
Chimeric antigen receptor T-cell therapies are promising new options for patients with relapsed or refractory diffuse large B-cell lymphoma or acute lymphoblastic leukaemia. They increase complete response rates and the chances of achieving prolonged remission. Chimeric antigen receptor T cells are specially modified lymphocytes designed to stimulate the body's own immune system to target malignant cells. The process involves an initial harvest of the patient's own T cells, genetic modification, T-cell expansion and then reinfusion. Cytokine release syndrome is a major short-term complication of chimeric antigen receptor T-cell therapy. The presentation typically resembles septic shock and can be fatal. Immune effector cell-associated neurotoxicity syndrome is another major short-term complication. It presents with a spectrum of neurological deficits ranging from headache, delirium and anxiety to seizures and coma. There are early promising results with chimeric antigen receptor T-cell therapies in other cancers. These include mantle cell lymphoma, multiple myeloma and some solid organ tumours such as glioblastoma multiforme.
MEMBER ACCOUNT
登录成功会直接打开下一页。
